

Date: 14/02/2018

Deputy Manager
Dept. of Corporate Services,
Bombay Stock Exchange Limited
P J Towers, Dalal Street,
Fort, MUMBAI - 400001

Sub: Outcome of Board Meeting held on 14th February, 2018.
Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 14th February, 2018 and transacted following business:

1. Approved Unaudited Standalone financial results for the quarter ended on 31st December, 2017. In compliance with the Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are herewith enclosing Unaudited Standalone Financial results for the quarter ended on 31st December, 2017 along with Limited Review Report issued by the Statutory Auditors of the company.
2. Considered and approved appointment of Mr. K.T.V. Kaladhar as Chief Financial Officer of the Company. We are herewith enclosing his brief profile.

The Board meeting commenced at 5.00 PM and ended at 6.45 PM

This is for your record and reference.

Thanking you,

Yours faithfully,
For Vivo Bio Tech Limited

KALYAN RAM
MANGIPUDI

Digitally signed by
KALYAN RAM MANGIPUDI
Date: 2018.02.14 18:56:23
+05'30'

M Kalyan Ram
Whole Time Director
DIN: 02012580

K.T.V. Kaladhar

1.Name	K.T.V. Kaladhar
Date of Birth	17-02-1973
Date of Appointment	14 th February,2018
Qualifications:	M.Com
Expertise in Specific Functional Areas:	20 years of experience in Finance , Accounting, Audit & Taxations Fields across multiple industries. Worked with M/s. Vijaya Diagnostic Centre Pvt Ltd and was in-charge of the Fund Management and Statutory Compliances. Worked with Ratanam Dhaveji & Co, Chartered Accounts in the area of Internal & Statutory Audits.
Directorships held in other public companies (Excluding Foreign companies and Section 8 Companies)	NIL
Memberships/Chairmanships of Committees of other public Companies (Includes Only Audit Committee and Stakeholder's Relationship Committee)	NIL
Number of shares held in the company	NIL
Relationship between directors inter-se	There is no relationship with other directors on the board

Rs.in Lakhs							
Statement of Standalone Unaudited Financial Results for the Quarter 31st December,2017							
S.No.	PARTICULARS	QUARTER ENDED			Nine Months Ended		Year Ended
		31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	1,206.98	1,163.84	847.78	3,467.15	2,557.83	3412.80
II	Other income	-	-	-	12.74	35.95	39.56
III	Total Income	1,206.98	1,163.84	847.78	3,479.89	2,593.78	3,452.36
IV	Expenses						
	a) Increase/(decrease) in stock in trade and WIP	(50.01)	(4.86)	(142.85)	(393.13)	(102.04)	(47.72)
	b) Consumption of Raw materials	-	-	296.83	-	702.75	862.08
	c) Purchase of traded goods	294.43	231.67	-	933.56	-	-
	d) Employees Cost	178.31	186.86	133.06	585.07	401.89	549.51
	e) Depreciation and amortisation	144.66	111.58	99.72	371.92	280.37	390.13
	f) Finance Cost	63.69	62.58	57.08	174.91	75.41	128.88
	g)Administrative Expenditure	467.83	476.52	307.05	1,519.38	946.58	1285.94
	Total	1,098.91	1,064.35	750.89	3,191.71	2,304.96	3,168.82
V	Profit before Exceptional and Extraordinary Items and Tax	108.08	99.49	96.89	288.19	288.82	283.54
VI	Exceptional items	-	-	-	-	-	-
VII	Profit before Extraordinary Items and Tax	108.08	99.49	96.89	288.19	288.82	283.54
VIII	Extraordinary Items	-	-	-	-	-	-
IX	Profit before tax	108.08	99.49	96.89	288.19	288.82	283.54
X	Tax Expense						
	a. Current Tax	22.50	18.96	24.22	54.91	60.56	39.03
	b. Deferred tax	10.47	(7.10)	-	2.67	-	(5.88)

Vivo Bio Tech Ltd.
Your Drug Discovery Partner

XI	Profit for the Period from continuing activities	75.11	87.64	72.67	230.60	228.26	250.39
XII	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	75.11	87.64	72.67	230.60	228.26	250.39
XVI	Other Comprehensive Income						
	a. i. Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	ii. Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	b. i. Items that will be reclassified to profit or loss	0.28	0.28	0.28	0.84	0.84	-
	ii. Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	0.28	0.28	0.28	0.84	0.84	-
XVII	Total Comprehensive Income(XV+XVI)	75.39	87.92	72.95	231.44	229.10	250.39
XVIII	Earnings per equity share:						
	1)Basic	0.81	0.94	0.78	2.48	2.45	2.68
	2)Diluted	0.81	0.94	0.78	2.48	2.45	2.68

Place: Hyderabad
Dated:14/02/2018

For Vivo Bio Tech Limited

KALYAN
RAM
MANGIPUDI
Date: 2018.02.14
18:53:52 +05'30'

M Kalyan Ram
Whole Time Director
DIN: 02012580

Address for Correspondence: 3 Floor, Ilyas Mohammed Khan Estate, 8-2-672/5&6, Road No.1, Banjara hills, Hyderabad - 500034, Telangana, India; **Address of Preclinical Research Facility:** Sy.No.349/A, Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana, INDIA; Email Id: investors@vivobio.com Website: www.vivobio.com.

Notes

1. The Company has adopted IND AS with effect from 01st April, 2017 with comparatives being restated. Accordingly impact of the of transition has been provided in the previous year's quarterly and nine months period results
2. The above financial results are recommended by the Audit Committee were considered and approved by the board of directors at their meeting held on 14th February,2018.
3. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required
4. An Extract of the detailed format of unaudited financial results filed with stock exchange under Regulation 33 of SEBI(Listing Obligations and Disclosure Requirements) Regulations,2015 will be published in Newspaper.
5. Previous year's/period's figures are rearranged/ regrouped wherever necessary

Date: 14th February, 2018

Place: Hyderabad

For Vivo Bio Tech Limited

KALYAN
RAM
MANGIPUDI

Digitally signed by
KALYAN RAM
MANGIPUDI
Date: 2018.02.14
18:52:57 +05'30'

M Kalyan Ram

Whole Time Director

DIN: 02012580



CHANDRA BABU NAIDU & CO.,
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.


Tel. : (91-40) 2311 9499
Mob. : +91-97032 24490
E-mail : chandrababu.ca@gmail.com

LIMITED REVIEW REPORT

To
The Board of Directors
M/s. Vivo Bio Tech Limited
Hyderabad

Limited Review Report for the quarter and nine months ended 31st December, 2017

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of M/s. Vivo Bio Tech Limited for the quarter ended 31st December 2017 and year to date from April 1st 2017 to December 31st 2017 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/ CFD/FAC / 62 / 2016 dated July 5th, 2016.
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 14-02-2018. Our responsibility is to issue a report on "the statement" based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Ind AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.







CHANDRA BABU NAIDU & CO.,
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
Mob. : +91-97032 24490
E-mail : chandrababu.ca@gmail.com

5. The accompanying Ind AS financial results and other financial information for the corresponding quarter ended December 31st 2016 and year to date from April 1st 2016 to December 31st 2016 have not been reviewed and presented solely based on the information compiled by management and has been approved by the Board of Directors.

For Chandra Babu Naidu & Co.,
Chartered Accountants
FRN: 016016S


Chandra babu M
Partner
M.No. 227849



Place: Hyderabad
Date: 14-02-2018